Alterome Therapeutics
PrivateLast Round
Series B
Apr 3, 2024
Total Funding Raised
$231M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alterome Therapeutics is a biopharmaceutical company that develops alteration-specific targeted therapies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alterome Therapeutics Comparables
Compare Alterome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terremoto Biosciences | 90% | |
| Atavistik Bio | 89% | |
| Delphia Therapeutics | 79% |
Alterome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 3, 2024 | ||||
| Series A Extension | Nov 2, 2022 | ||||
| Series A | Jan 19, 2022 |
Key People
Founding team and executive leadership
Alterome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boxer Capital | Series A Extension, Series B, Series A |
| Digitalis Ventures | Series B |
| Vida Ventures | Series A Extension, Series B, Series A |
| Blue Owl Capital | Series B |
| OrbiMed | Series B, Series A Extension, Series A |
| Invus Opportunities | Series B |
| Canaan Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 41% MoM, reaching 5K.
- Feb 2, 2026
Leonardo Faoro appointed as new Chief Medical Officer.
Recent news
Latest coverage and updates
- hiresSep 8, 2026
Alterome Therapeutics, Inc. hired Johanna Mylet as chief financial officer on Sep 8th '26.
Alterome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alterome Therapeutics's valuation, stock price, and market status.
Is Alterome Therapeutics a public or private company?
Alterome Therapeutics is a private company.
What is the current stock price of Alterome Therapeutics?
Alterome Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Alterome Therapeutics worth (valuation)?
Valuation information for Alterome Therapeutics is not publicly available.
Can I buy Alterome Therapeutics stock?
Alterome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Alterome Therapeutics's last funding round?
Alterome Therapeutics's most recent funding round was Series B on April 3, 2024.
Who are the main investors in Alterome Therapeutics?
Key investors in Alterome Therapeutics include OrbiMed, Colt Ventures, Goldman Sachs Alternatives.
Will Alterome Therapeutics IPO soon?
No public IPO plans have been announced for Alterome Therapeutics.
How can I track Alterome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alterome Therapeutics's secondary market activity and sign up for updates.